Loading...
Impact of high-risk classification by FISH: An Eastern Cooperative Oncology Group (ECOG) study E4A03
Lenalidomide with dexamethasone is a standard induction treatment regimen for newly diagnosed myeloma (although a Federal Drug Administration indication is still absent). In the context of the Phase 3 clinical trial E4A03 (lenalidomide plus dexamethasone in low or high doses), we queried whether a f...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3192237/ https://ncbi.nlm.nih.gov/pubmed/21902684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08849.x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|